Virbac SA Total Assets
Virbac SA total assets. Based on the latest financial reports, Virbac SA (VIRP) holds total assets worth €1.82 Billion EUR (≈ $2.12 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see VIRP market cap for the company's overall valuation and market capitalisation.
Total Assets of Virbac SA (2002–2024)
Total assets of Virbac SA from 2002 to 2024. This chart illustrates how Virbac SA's total assets have evolved over time, based on quarterly financial data. See current stock price of Virbac SA for real-time trading data and today's change.
Virbac SA - Asset Composition Analysis
Virbac SA Total Assets Breakdown (December 2024)
Virbac SA total assets breakdown as of December 2024. Virbac SA's total assets of €1.82 Billion consist of 45.7% current assets and 54.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.1% |
| Accounts Receivable | €268.68 Million | 14.5% |
| Inventory | €404.17 Million | 21.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €251.24 Million | 13.6% |
| Goodwill | €276.63 Million | 15.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Virbac SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Virbac SA working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Virbac SA's current assets represent 45.7% of total assets in 2024, a decrease from 62.9% in 2002.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2024, up from 0.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 9.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 21.9% of total assets.
Virbac SA Competitors by Total Assets
Key competitors of Virbac SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
|
Organon & Co
NYSE:OGN
|
USA | $13.18 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥12.85 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
Virbac SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 1.65 | 2.28 |
| Quick Ratio | 1.04 | 0.89 | 1.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €411.65 Million | €346.67 Million | €443.14 Million |
Virbac SA - Advanced Valuation Insights
This section examines the relationship between Virbac SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.83 |
| Latest Market Cap to Assets Ratio | 1.63 |
| Asset Growth Rate (YoY) | 27.0% |
| Total Assets | €1.85 Billion |
| Market Capitalization | $3.01 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Virbac SA's assets above their book value (1.63x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Virbac SA's assets grew by 27.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Virbac SA (2002–2024)
The table below shows the annual total assets of Virbac SA from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €1.85 Billion ≈ $2.16 Billion |
+26.98% |
| 2023-12-31 | €1.46 Billion ≈ $1.70 Billion |
+7.03% |
| 2022-12-31 | €1.36 Billion ≈ $1.59 Billion |
+11.12% |
| 2021-12-31 | €1.22 Billion ≈ $1.43 Billion |
+10.32% |
| 2020-12-31 | €1.11 Billion ≈ $1.30 Billion |
-16.15% |
| 2019-12-31 | €1.32 Billion ≈ $1.55 Billion |
+3.96% |
| 2018-12-31 | €1.27 Billion ≈ $1.49 Billion |
-0.35% |
| 2017-12-31 | €1.28 Billion ≈ $1.49 Billion |
-9.87% |
| 2016-12-31 | €1.42 Billion ≈ $1.66 Billion |
-0.94% |
| 2015-12-31 | €1.43 Billion ≈ $1.67 Billion |
+7.90% |
| 2014-12-31 | €1.33 Billion ≈ $1.55 Billion |
+47.94% |
| 2013-12-31 | €896.23 Million ≈ $1.05 Billion |
+8.28% |
| 2012-12-31 | €827.70 Million ≈ $967.67 Million |
+40.61% |
| 2011-12-31 | €588.63 Million ≈ $688.18 Million |
+10.28% |
| 2010-12-31 | €533.75 Million ≈ $624.01 Million |
+22.85% |
| 2009-12-31 | €434.47 Million ≈ $507.94 Million |
+5.29% |
| 2008-12-31 | €412.66 Million ≈ $482.44 Million |
+9.56% |
| 2007-12-31 | €376.64 Million ≈ $440.33 Million |
-0.59% |
| 2006-12-31 | €378.87 Million ≈ $442.93 Million |
+20.53% |
| 2005-12-31 | €314.32 Million ≈ $367.48 Million |
+6.86% |
| 2004-12-31 | €294.13 Million ≈ $343.87 Million |
+3.09% |
| 2003-12-31 | €285.31 Million ≈ $333.56 Million |
+6.96% |
| 2002-12-31 | €266.74 Million ≈ $311.85 Million |
-- |
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. I… Read more